<DOC>
	<DOCNO>NCT01975844</DOCNO>
	<brief_summary>Hypothesis : Routine clinical test feedback control base Epogen ( Epo ) /Venofer ( Iron ) protocol improve Hemoglobin ( Hgb ) stability increase time patient remain target Objectives : 1 . Decreased variability Hgb 2 . Increase % patient target range c Increase time Hgb remain target range</brief_summary>
	<brief_title>The Effect Epogen Venofer Dosing Management Hemoglobin Stability</brief_title>
	<detailed_description>Study Design One dialysis unit shift comprise 200 patient . Study participation last 12 month break 3 phase describe . Phase 1 ( 1-3 month ) : Develop individualized patient model Anemia Management Protocols ( AMP ) patient receive standard medical care . Phase 2 ( 9 month ) : Individualized AMP study period . Phase 3 ( 9 month ) : Follow period : return standard-care AMP . The individual AMP utilized weekly 9 month Phase 2 . The 3 objective evaluate updated weekly , Baseline Year 1 . All Epo dose recommendation must review treat physician either accept modify dose his/her discretion base clinical event include transmit data bleeding , infection , hospitalization .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>18 year old old Receiving hemodialysis outpatient dialysis unit Not receive EPOGEN part standard medical care Patient refusal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Anemia</keyword>
	<keyword>End Stage Renal Disease</keyword>
</DOC>